CD34 and stroke disorder: Similarly, Chen et al. showed in a randomized, single-blind, controlled trial that autologous G-CSF mobilized CD34+ therapy improved the NIHSS, the European stroke score (ESS), and the ESS motor score without any serious adverse events in patients with a MCAI (Chen et al., 2014).